Drug Profile
Research programme: serine hydrolase inhibitors - Lundbeck/SCYNEXIS
Latest Information Update: 02 Jul 2019
Price :
$50
*
At a glance
- Originator Abide Therapeutics
- Developer Abide Therapeutics; SCYNEXIS
- Class
- Mechanism of Action Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Parasitic infections; Viral infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Parasitic-infections in USA
- 16 Jul 2016 No recent reports of development identified for research development in Viral-infections in USA
- 29 Mar 2012 Early research in Parasitic infections in USA (unspecified route)